---
title: "Regeneron Q2 revenue beats on higher Dupixent, Eylea HD sales"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294348341.md"
datetime: "2026-07-30T10:50:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294348341.md)
  - [en](https://longbridge.com/en/news/294348341.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294348341.md)
---

# Regeneron Q2 revenue beats on higher Dupixent, Eylea HD sales

) Overview

-   U.S. biotechnology firm’s Q2 revenue grew 17% yr/yr, beating analyst expectations
-   Adjusted EPS for Q2 rose 11% yr/yr, beating analyst expectations
-   Company repaid Sanofi Development Balance, boosting future collaboration profits Outlook
-   Regeneron raised 2026 GAAP gross margin guidance on net product sales to 78%-79% from 77%-78%
-   Company lowered 2026 capital expenditures forecast to $1.03-$1.1 bln from $1.1-$1.2 bln
-   Regeneron says collaboration profits will increase from Q3 after full repayment of Sanofi Development Balance Result Drivers
-   DUPIXENT SALES - Higher Dupixent sales drove a significant increase in collaboration revenue, with global net sales rising 38%
-   EYLEA HD DEMAND - U.S. EYLEA HD net sales rose 52% to a record high, driven by increased demand and higher sales volumes
-   LIBTAYO GROWTH - Libtayo global net sales increased 30%, primarily due to higher sales volumes driven by increased demand Company press release: Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $4.29 $3.82

Revenue bln bln (20

Analysts

)

Q2 Beat $14.29 $10.26

Adjusted (22

EPS Analysts

)

### Q2 EPS $12.23

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 20 “strong buy” or “buy”, 10 “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the pharmaceuticals peer group is “buy”
-   Wall Street’s median 12-month price target for Regeneron Pharmaceuticals Inc is $816.79, about 17.5% above its July 29 closing price of $695.42
-   The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 16 three months ago Reuters Recommended Reads
-   July 30 - Sanofi lifts sales growth forecast on Dupixent strength in boost for new CEO
-   July 29 - Biogen beats quarterly estimates as newer drugs drive growth
-   July 29 - J&J lowers 2026 profit forecast on deal costs, sees further hit in 2027 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [NewEdge Advisors LLC Has $5.88 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/295508474.md)
- [Regeneron publishes corporate presentation highlighting Q2 pipeline progress and product sales trends](https://longbridge.com/en/news/294365385.md)
- [12:37 ETREGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit](https://longbridge.com/en/news/294851069.md)
- [Sanofi asked to change Dupixent ads after Galderma challenge](https://longbridge.com/en/news/295117261.md)
- [CTMX: Varseta-M advances in CRC and GI cancers, supported by strong cash and expanded Regeneron collaboration](https://longbridge.com/en/news/295154296.md)